Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26-Week (With 26 Week Extension) Randomized, Multi-Center, Double-Blind Phase 2 Study to Evaluate the Efficacy and Safety of XC001 Gene Therapy as an Adjunct to Coronary Artery Bypass Graft Surgery for Patients With Symptomatic Coronary Artery Disease With Left Ventricular Dysfunction at Risk for Incomplete Revascularization

Next Previous
Trial Profile

A 26-Week (With 26 Week Extension) Randomized, Multi-Center, Double-Blind Phase 2 Study to Evaluate the Efficacy and Safety of XC001 Gene Therapy as an Adjunct to Coronary Artery Bypass Graft Surgery for Patients With Symptomatic Coronary Artery Disease With Left Ventricular Dysfunction at Risk for Incomplete Revascularization

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Encoberminogene rezmadenovec (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms EXACT-CABG
  • Sponsors XyloCor Therapeutics

Most Recent Events

  • 12 Aug 2025 Status changed from planning to not yet recruiting.
  • 07 Jan 2025 According to XyloCor Therapeutics media release, company aims to initiate a second Phase 2 trial of XC001 in 2025 as an adjunctive therapy to augment the effectiveness of CABG
  • 10 Jul 2024 According to XyloCor Therapeutics media release, the company have entered into a licensing agreement under which XyloCor has rights to the Extroducer Infusion Catheter System , a first-in-class endovascular device designed to deliver advanced therapies directly into the heart; XyloCor plans to deploy the Extroducer to support catheter-based endocardial delivery of XC001

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top